AWAK PD Attracts Funding
Singapore-based Awak PD won FDA breakthrough device designation after completing its first-in-human study in October 2018, with no serious adverse events, and has now raised $40M in a financing round to support late-stage clinical studies and commercialization of its portable, wearable, sorbent-based PD device.
Read the full article » | Posted 01-09-2020
Related Articles
- Xeltis is Trialing its Polymer-based Vascular Access Posted 03-12-2026
- New Bluetooth-enabled CAPD System Enhanced Patient Satisfaction Posted 03-12-2026
- Emerging Biomarker Research in PD Posted 03-12-2026
- Byonyks’ X1 APD Cycler Received FDA 510(k) Approval Last Summer Posted 02-17-2026

